Guérin M, Barrois M, Terrier M J, Spielmann M, Riou G
Laboratoire de Pharmacologie Clinique et Moléculaire, Institut Gustave Roussy, Villejuif, France.
Oncogene Res. 1988;3(1):21-31.
Tumor specimens from 116 untreated patients with primary breast carcinoma at different clinical stages were analyzed for the structure and/or the expression of c-myc and c-erbB-2/neu proto-oncogenes. An amplification of the c-myc proto-oncogene (3 to greater than 50 fold) was detected only in 6% of carcinomas, with no evidence of locus rearrangement. High c-myc RNA levels detected in 45% of tumors were found significantly (p less than 0.01) correlated with lymph node involvement. Amplification (3 to greater than 30 fold) of the c-erbB-2/neu gene was observed in 20% of cancers. A 5 kb c-erbB-2/neu gene transcript was detected in the 103 cancer specimens analyzed. High levels of transcripts were observed in 36% of tumors. Overexpression did not depend only on amplification since found in 14 tumor samples with a single gene copy. The gene amplification and overexpression were found significantly associated with cancers of poor prognosis. Moreover our data show that both proto-oncogenes are overexpressed only in 12.5% of tumor samples and suggest that each gene might play a different role in tumor progression.
对116例未经治疗的处于不同临床阶段的原发性乳腺癌患者的肿瘤标本进行了分析，以检测c-myc和c-erbB-2/neu原癌基因的结构和/或表达情况。仅在6%的癌组织中检测到c-myc原癌基因扩增（3至大于50倍），且无基因座重排证据。在45%的肿瘤中检测到高c-myc RNA水平，发现其与淋巴结受累显著相关（p<0.01）。在20%的癌症中观察到c-erbB-2/neu基因扩增（3至大于30倍）。在分析的103个癌症标本中检测到5kb的c-erbB-2/neu基因转录本。在36%的肿瘤中观察到高水平的转录本。过表达并不仅取决于扩增，因为在14个单基因拷贝的肿瘤样本中也发现了过表达。发现基因扩增和过表达与预后不良的癌症显著相关。此外，我们的数据表明，仅在12.5%的肿瘤样本中两个原癌基因均过表达，并提示每个基因在肿瘤进展中可能发挥不同作用。
